Why did the U.S. FDA decline to review the new mRNA influenza vaccine?

2026-02-13 - 12:45

The debate here is not about the legitimacy of mRNA vaccines. It is about whether the right comparator was chosen in a clinical trial — and whether that design is sufficient for regulatory review